National registry enabled this analysis focusing on natural killer cell licensing and leukemia type.
Distinct susceptibility to donor natural killer cells exists between acute myeloid leukemia and acute lymphoid leukemia.
Transiently activated C1/C1 NK-cells appeared to target C1/C2 acute myeloid leukemia cells after stem cell transplantation.
Alloreactivity by natural killer cell may be masked when HLA-C–mismatch exists.
Donor HLA-C group for KIR2DL impacts on the outcome after HLA-C–mismatched stem cell transplantation.